EP2741754A1 - Use of a polysaccharide polymer from the seeds of the tamarind tree in protecting against tobacco-associated damages - Google Patents

Use of a polysaccharide polymer from the seeds of the tamarind tree in protecting against tobacco-associated damages

Info

Publication number
EP2741754A1
EP2741754A1 EP12735548.5A EP12735548A EP2741754A1 EP 2741754 A1 EP2741754 A1 EP 2741754A1 EP 12735548 A EP12735548 A EP 12735548A EP 2741754 A1 EP2741754 A1 EP 2741754A1
Authority
EP
European Patent Office
Prior art keywords
use according
preparation
seeds
tamarind
smoke
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP12735548.5A
Other languages
German (de)
French (fr)
Other versions
EP2741754B1 (en
Inventor
Marco Sardina
Adonella ALETTI
Elsa Melloni
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zambon SpA
Original Assignee
Zambon SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zambon SpA filed Critical Zambon SpA
Priority to SI201230267T priority Critical patent/SI2741754T1/en
Priority to PL12735548T priority patent/PL2741754T3/en
Priority to EP12735548.5A priority patent/EP2741754B1/en
Publication of EP2741754A1 publication Critical patent/EP2741754A1/en
Application granted granted Critical
Publication of EP2741754B1 publication Critical patent/EP2741754B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Definitions

  • the present invention relates to the use of polysaccharide polymer obtained from the seeds of the tamarind tree for protecting the epithelial cells of the respiratory tract by damages induced by tobacco smoke.
  • the present invention relates to the use of polysaccharide polymer obtained from the seeds of the tamarind tree for protecting the airway epithelial cells of the respiratory airways from damages induced by smoke of cigarettes, cigars or pipes.
  • the human nasopharyngeal epithelium a sentinel site of respiratory tract immunity, is constantly exposed to microbial patterns and other environmental stimuli.
  • cigarette smoke can be considered one of the most dangerous environmental stresses, bringing about structural changes in the respiratory tract as well as alterations in immune responses that may lead to predisposition to infection or exacerbation of existing pathologies.
  • COPD chronic obstructive pulmonary disease
  • Damage to airway epithelial cells by tobacco smoke, particularly cigarette smoke, is therefore intimately related to the pathogenesis of a variety of acute and chronic respiratory disorders.
  • Tamarind tree is widespread in India, Africa and in the South East Asia.
  • tamarind juice from the tamarind fruit can be a drink prepared by infusing dried tamarind pulp.
  • Tamarind can also be useful for the preservation of food products and as a sauce in recipes.
  • the tamarind seed finds various applications, once ground to the powder form (known as "tamarind gum” or “tamarind kernel powder”).
  • tamarind kernel powder can be employed as thickener and a sizing agent in textile and paper industries; and as thickening, gelling, stabilizing and binding agent in food and pharmaceutical industries.
  • a polysaccharide polymer obtained from the seeds of the tamarind tree provides protection to airway epithelial cells against tobacco smoke-induced damages, by preserving epithelial barrier integrity and hence, preventing structural changes in the respiratory tract that may lead to predisposition to infection or exacerbation of existing acute and chronic respiratory disorders.
  • tamarind seed polysaccharide obtained from the seeds of the tamarind tree (tamarind seed polysaccharide), for use in protecting airway epithelial cells against tobacco smoke-induced damages.
  • the present invention relates to the protection of airway epithelial cells damages caused by cigarette smoke, through the administration of a polysaccharide polymer obtained from the seeds of the tamarind tree (tamarind seed polysaccharide).
  • the local administration to the epithelial cells of the respiratory airways of a smoker or a second-hand smoker of a preparation containing the tamarind seed polysaccharide according to the invention plays an effective role in protecting airway epithelial cells against tobacco smoke-induced damages, particularly cigarette smoke-induced damages.
  • Tamarind seed polysaccharide is a nonionic, neutral, branched polysaccharide comprising a cellulose-like backbone substituted by xylose (a 1 ⁇ 6) and galacto ( ⁇ l ⁇ 2)xylose (a 1 ⁇ 6) substituents (Lang P. et al., Macro molecules, 1993, 26, 3992- 3998).
  • Tamarind seed polysaccharide suitable for the preparations according to the present invention may be obtained according to any method known in the art, preferably following the methods described in WO 97/28787.
  • a polysaccharide polymer obtained from the seeds of the tamarind tree according to the invention can be locally administered preferably as an aerosolized liquid preparation, by suitable commercially available inhalation devices, to the mucous membranes of the respiratory airways of a cigarette smoker or a second-hand smoker (herein also named as passive-smoker), namely a person who involuntarily takes environmental smoked tobacco of a cigarette smoker.
  • a preparation in the form of a liquid dosage for topical application, particularly aerosolized topical application which comprises a polysaccharide polymer obtained from the seeds of the tamarind tree, said preparation being useful in protecting airway epithelial cells against tobacco smoke-induced damages, particularly cigarette smoke-induced damages.
  • the preparation according the invention contains from 0.25 to 0.5 w/v% (hereunder the unit “w/v%” is referred to as "%" for simplicity) of the polysaccharide polymer obtained from the seeds of the tamarind tree.
  • the preparation according the invention contains 0.3% of the polysaccharide polymer obtained from the seeds of the tamarind tree.
  • the preparation according to the invention can further comprise pH adjusting agents well known to a person skilled in the art, including pharmaceutically acceptable acids or bases and buffering agents.
  • the acids may include one or more inorganic mineral acids such as hydrochloric, hydrobromic, sulphuric, phosphoric and nitric acid, or one or more organic acids such as acetic, succinic, tartaric, ascorbic, citric, glutamic, benzoic, methanesulphonic, ethanesulfonic and trifluoroacetic acid.
  • the bases may include inorganic bases and organic bases, such as alkaline carbonate, alkaline bicarbonate, alkaline earth metal carbonate, alkaline hydroxide and alkaline earth metal hydroxide.
  • the inorganic base may be an alkaline hydroxide such as lithium hydroxide, potassium hydroxide, cesium hydroxide or sodium hydroxide; an alkaline carbonate may be calcium carbonate or sodium carbonate; an alkaline bicarbonate may be sodium bicarbonate.
  • buffering agents include a phosphate buffer such as sodium dihydrogen phosphate commonly termed monosodium phosphate (NaH 2 P0 4 ) and disodium hydrogen phosphate commonly termed disodium phosphate (Na 2 HP0 4 ), an acetate buffer (sodium acetate- acetic acid system) a citrate buffer (sodium citrate-citric acid system) and mixtures thereof.
  • the buffering agent is preferably selected from monosodium phosphate (NaH 2 PC>4), disodium phosphate (Na 2 HP0 4 ) or mixture thereof, and sodium citrate-citric acid system.
  • the type and concentration of the pH adjusting agents suitable for use in the disclosed preparation would be dependent on the desired pH value which ranges within 6.0 to 8.0, preferably within 6.8 and 7.5.
  • the isotonicity of the preparation vehicle is preferably adjusted by sodium chloride.
  • the local administration to the epithelial cells of the respiratory airways of a smoker or a second-hand smoker of the preparation according to the invention can be carried out by an aerosol delivery system.
  • the aerosolized liquid preparation is therefore sufficiently mobile to coat a wide area of the airway epithelial cells of the respiratory tract, thus providing protective effect to epithelial barrier integrity.
  • the aerosol delivery system is a commercially available nebulizer, such as a jet nebulizer, which accepts the liquid preparation and transforms said liquid preparation into fine droplets, so that it can be easily inhaled through a mouthpiece or a face mask.
  • a jet nebulizer such as a jet nebulizer
  • a jet of air is forced through the preparation according to the invention, turning it into fine droplets which are moved along a tube.
  • the subject inhales the preparation, through a mouthpiece or a face mask.
  • a face mask is preferably used for pediatric subjects.
  • the amount of the preparation administered to a subject may be dependent on a variety of factors, including the general quality of health, age, gender, weight of the subject in need thereof. For example, from 6 to 18 mg/day of tamarind seed polysaccharide can be administered to a subject in need thereof.
  • a process for preparing a preparation as described above can be carried out according to methods well known to a person skilled in the art; for example, said process comprises dissolving the tamarind seed polysaccharide in purified water such as water for injections and adding a pH adjusting agent until the desired pH is reached.
  • airway epithelial cells means epithelial cells of the respiratory airways.
  • tobacco smoke includes beedi, cigar, filtered and unfiltered cigarette, pipe, hookah and kretek smoke.
  • inhalation or “administration by inhalation” refers to the introduction into the respiratory organs, especially into and/or via the airways, preferably into and/or via the nasal cavity and oral cavity.
  • the term “nebulizer” includes jet nebulizers.
  • the term “polysaccharide polymer obtained from the seeds of the tamarind tree”, interchangeable with the term “tamarind seed polysaccharide” and abbreviated as “TSP” means any polysaccharide-enriched fraction obtainable from tamarind kernel powder currently available on the market.
  • a partially purified polysaccharide fraction of tamarind gum is sold, for instance, by Dainippon Pharmaceutical Co. LTD of Osaka, Japan, under the trade name Glyloid ® .
  • the concerned polysaccharide is preferably obtained following any method known in the art to give a practically pure tamarind seed polysaccharide from commercial tamarind gum sources.
  • preparation is intended in a broader sense to include not only all conventional pharmaceutical preparations but also preparations useful as diet supplements, medical devices and food additives.
  • the term "subject” refers to a tobacco smoker, especially a cigarette smoker, or a second-hand smoker, namely a person who involuntarily takes environmental smoked tobacco of a tobacco smoker, especially a cigarette smoker.
  • a tobacco smoker especially a cigarette smoker
  • a second-hand smoker namely a person who involuntarily takes environmental smoked tobacco of a tobacco smoker, especially a cigarette smoker.
  • the following Examples illustrates but do not limit the present invention.
  • Cigarette Smoke Condensate is able to impair integrity and induce injury of airway epithelial cells.
  • TSP TSP in protecting airway epithelial cells from damages induced by CSC was investigated in vitro on Calu-3 human cell line.
  • TSP TSP
  • Calu-3 cells were exposed for 24 h to TSP 0.3% alone, to a cigarette smoke-induced injury alone (CSC 5%), or pre-incubated with TSP 0.3% for 1 hr before exposure to CSC 5% for 24h.
  • cell viability was determined by the Trypan Blue dye exclusion test, according to standard technique.
  • the percentage of cell survival was significantly lower in cultures exposed to CSC 5% as compared to control cultures grown in medium alone (59.95% and 83.08%, respectively; p ⁇ 0.05), whereas, surprisingly, the toxic effect of CSC was significantly prevented by pre-incubation of cells with 0.3% TSP (p ⁇ 0.05) since the percentage of cell survival on Calu-3 cultured with TSP alone or in association with CSC was similar to that reported for cell control (81.96% and 76.19%, respectively).
  • Fig. 1 shows Calu-3 survival cells after 24h of treatment with CSC 5% and/or TSP 0.3% by the Trypan Blue exclusion test.
  • TSP may contribute to the protection of the airway epithelium barrier against cigarette smoke-induced injury, by preserving epithelial barrier integrity.
  • TSP tamarind seed polysaccharide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)

Abstract

Use of a polysaccharide polymer obtained from the seeds of the tamarind tree for use in protecting the epithelial cells of the respiratory tract by damages induced by tobacco smoke.

Description

USE OF A POLYSACCHARIDE POLYMER FROM THE SEEDS OF THE TAMARIND SEED IN PROTECTING AGAINST TOBACCO -ASSOCIATED DAMAGES
FIELD OF THE INVENTION
The present invention relates to the use of polysaccharide polymer obtained from the seeds of the tamarind tree for protecting the epithelial cells of the respiratory tract by damages induced by tobacco smoke.
Especially, the present invention relates to the use of polysaccharide polymer obtained from the seeds of the tamarind tree for protecting the airway epithelial cells of the respiratory airways from damages induced by smoke of cigarettes, cigars or pipes.
DESCRIPTION OF THE INVENTION
According to R. Kulkarni et al. (Infection and Immunity, May 2010, p. 2146-2152) tobacco and, in particular, cigarette smoke and exposure to second-hand smoke are important risk factors for a variety of systemic and respiratory tract diseases that include six of the eight leading causes of death in the world (WHO. 2008. WHO report on global tobacco epidemic, 2008: the MPOWER package. World Health Organization, Geneva, Switzerland). Today, tobacco kills approximately 5 million people every year worldwide, and this number is estimated to rise to 8.3 million by 2030 (Mathers, C. D., and D. Loncar. 2006. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 3:e442).
Smokers are at particular risk of upper and lower respiratory tract infections.
The human nasopharyngeal epithelium, a sentinel site of respiratory tract immunity, is constantly exposed to microbial patterns and other environmental stimuli.
In particular, cigarette smoke can be considered one of the most dangerous environmental stresses, bringing about structural changes in the respiratory tract as well as alterations in immune responses that may lead to predisposition to infection or exacerbation of existing pathologies.
The gaseous and soluble phases of cigarette smoke contribute to the pathogenesis of chronic obstructive pulmonary disease (COPD). Chronic oxidative stress of cigarette smoking induces mucus secretion and inhibits cystic fibrosis transmembrane conductance regulator function. The increased mucus viscosity renders the airways susceptible to bacterial infections, a hallmark of chronic bronchitis.
Damage to airway epithelial cells by tobacco smoke, particularly cigarette smoke, is therefore intimately related to the pathogenesis of a variety of acute and chronic respiratory disorders.
Tamarind tree is widespread in India, Africa and in the South East Asia. In Middle Eastern countries, tamarind juice from the tamarind fruit can be a drink prepared by infusing dried tamarind pulp. Tamarind can also be useful for the preservation of food products and as a sauce in recipes.
The tamarind seed finds various applications, once ground to the powder form (known as "tamarind gum" or "tamarind kernel powder"). Commercially available tamarind kernel powder can be employed as thickener and a sizing agent in textile and paper industries; and as thickening, gelling, stabilizing and binding agent in food and pharmaceutical industries.
General properties, chemical composition and chemical structure of tamarind kernel powder and of tamarind seed polysaccharide can be found in: Gupta V, Puri R, Gupta S, Jain S, Rao GK.; Tamarind kernel gum: an upcoming natural polysaccharide. Syst Rev Pharm; 2010; 1 :50-4.
It has now surprisingly found that a polysaccharide polymer obtained from the seeds of the tamarind tree provides protection to airway epithelial cells against tobacco smoke-induced damages, by preserving epithelial barrier integrity and hence, preventing structural changes in the respiratory tract that may lead to predisposition to infection or exacerbation of existing acute and chronic respiratory disorders.
It is therefore a first object of the present invention a polysaccharide polymer obtained from the seeds of the tamarind tree (tamarind seed polysaccharide), for use in protecting airway epithelial cells against tobacco smoke-induced damages.
More specifically, the present invention relates to the protection of airway epithelial cells damages caused by cigarette smoke, through the administration of a polysaccharide polymer obtained from the seeds of the tamarind tree (tamarind seed polysaccharide).
The local administration to the epithelial cells of the respiratory airways of a smoker or a second-hand smoker of a preparation containing the tamarind seed polysaccharide according to the invention plays an effective role in protecting airway epithelial cells against tobacco smoke-induced damages, particularly cigarette smoke-induced damages.
Tamarind seed polysaccharide is a nonionic, neutral, branched polysaccharide comprising a cellulose-like backbone substituted by xylose (a 1→6) and galacto (β l→2)xylose (a 1→6) substituents (Lang P. et al., Macro molecules, 1993, 26, 3992- 3998).
Tamarind seed polysaccharide suitable for the preparations according to the present invention may be obtained according to any method known in the art, preferably following the methods described in WO 97/28787.
To achieve the desired effect, a polysaccharide polymer obtained from the seeds of the tamarind tree according to the invention can be locally administered preferably as an aerosolized liquid preparation, by suitable commercially available inhalation devices, to the mucous membranes of the respiratory airways of a cigarette smoker or a second-hand smoker (herein also named as passive-smoker), namely a person who involuntarily takes environmental smoked tobacco of a cigarette smoker.
It is therefore another object of the present invention a preparation in the form of a liquid dosage for topical application, particularly aerosolized topical application, which comprises a polysaccharide polymer obtained from the seeds of the tamarind tree, said preparation being useful in protecting airway epithelial cells against tobacco smoke-induced damages, particularly cigarette smoke-induced damages. The preparation according the invention contains from 0.25 to 0.5 w/v% (hereunder the unit "w/v%" is referred to as "%" for simplicity) of the polysaccharide polymer obtained from the seeds of the tamarind tree. Preferably, the preparation according the invention contains 0.3% of the polysaccharide polymer obtained from the seeds of the tamarind tree. The preparation according to the invention can further comprise pH adjusting agents well known to a person skilled in the art, including pharmaceutically acceptable acids or bases and buffering agents. For example, the acids may include one or more inorganic mineral acids such as hydrochloric, hydrobromic, sulphuric, phosphoric and nitric acid, or one or more organic acids such as acetic, succinic, tartaric, ascorbic, citric, glutamic, benzoic, methanesulphonic, ethanesulfonic and trifluoroacetic acid. The bases may include inorganic bases and organic bases, such as alkaline carbonate, alkaline bicarbonate, alkaline earth metal carbonate, alkaline hydroxide and alkaline earth metal hydroxide. For example, the inorganic base may be an alkaline hydroxide such as lithium hydroxide, potassium hydroxide, cesium hydroxide or sodium hydroxide; an alkaline carbonate may be calcium carbonate or sodium carbonate; an alkaline bicarbonate may be sodium bicarbonate. For example, buffering agents include a phosphate buffer such as sodium dihydrogen phosphate commonly termed monosodium phosphate (NaH2P04) and disodium hydrogen phosphate commonly termed disodium phosphate (Na2HP04), an acetate buffer (sodium acetate- acetic acid system) a citrate buffer (sodium citrate-citric acid system) and mixtures thereof.
In a particular aspect of the present invention, the buffering agent is preferably selected from monosodium phosphate (NaH2PC>4), disodium phosphate (Na2HP04) or mixture thereof, and sodium citrate-citric acid system.
The type and concentration of the pH adjusting agents suitable for use in the disclosed preparation would be dependent on the desired pH value which ranges within 6.0 to 8.0, preferably within 6.8 and 7.5.
The isotonicity of the preparation vehicle is preferably adjusted by sodium chloride. The local administration to the epithelial cells of the respiratory airways of a smoker or a second-hand smoker of the preparation according to the invention can be carried out by an aerosol delivery system. The aerosolized liquid preparation is therefore sufficiently mobile to coat a wide area of the airway epithelial cells of the respiratory tract, thus providing protective effect to epithelial barrier integrity.
Preferably, the aerosol delivery system is a commercially available nebulizer, such as a jet nebulizer, which accepts the liquid preparation and transforms said liquid preparation into fine droplets, so that it can be easily inhaled through a mouthpiece or a face mask.
As an example, when the jet nebulizer is turned on, a jet of air is forced through the preparation according to the invention, turning it into fine droplets which are moved along a tube. The subject inhales the preparation, through a mouthpiece or a face mask. A face mask is preferably used for pediatric subjects.
The amount of the preparation administered to a subject may be dependent on a variety of factors, including the general quality of health, age, gender, weight of the subject in need thereof. For example, from 6 to 18 mg/day of tamarind seed polysaccharide can be administered to a subject in need thereof.
A process for preparing a preparation as described above can be carried out according to methods well known to a person skilled in the art; for example, said process comprises dissolving the tamarind seed polysaccharide in purified water such as water for injections and adding a pH adjusting agent until the desired pH is reached.
As used herein, the singular forms "a," "an" and "the" include plural referents unless the context clearly states otherwise. Thus, for example, reference to "a polysaccharide polymer obtained from the seeds of the tamarind tree" includes mixtures of polysaccharide polymers obtained from the seeds of the tamarind tree. As used herein, the term "airway epithelial cells" means epithelial cells of the respiratory airways.
As used herein, the term "tobacco smoke" includes beedi, cigar, filtered and unfiltered cigarette, pipe, hookah and kretek smoke.
As used herein, the term "alleviation" includes mitigation, decrease, diminution and reduction.
As used herein, the term "inhalation" or "administration by inhalation" refers to the introduction into the respiratory organs, especially into and/or via the airways, preferably into and/or via the nasal cavity and oral cavity.
As used herein, the term "nebulizer" includes jet nebulizers. As used herein, the term "polysaccharide polymer obtained from the seeds of the tamarind tree", interchangeable with the term "tamarind seed polysaccharide" and abbreviated as "TSP", means any polysaccharide-enriched fraction obtainable from tamarind kernel powder currently available on the market. A partially purified polysaccharide fraction of tamarind gum is sold, for instance, by Dainippon Pharmaceutical Co. LTD of Osaka, Japan, under the trade name Glyloid®. For the purpose of the present invention, however, the concerned polysaccharide is preferably obtained following any method known in the art to give a practically pure tamarind seed polysaccharide from commercial tamarind gum sources.
As used herein, the term "preparation" is intended in a broader sense to include not only all conventional pharmaceutical preparations but also preparations useful as diet supplements, medical devices and food additives.
As used herein, the term "subject" refers to a tobacco smoker, especially a cigarette smoker, or a second-hand smoker, namely a person who involuntarily takes environmental smoked tobacco of a tobacco smoker, especially a cigarette smoker. The following Examples illustrates but do not limit the present invention.
Example 1
Cigarette Smoke Condensate (CSC) is able to impair integrity and induce injury of airway epithelial cells.
The efficacy of TSP in protecting airway epithelial cells from damages induced by CSC was investigated in vitro on Calu-3 human cell line.
The necessary amount of TSP was diluted in culture medium to reach the 0.3% (g/ml) concentration.
Calu-3 cells were exposed for 24 h to TSP 0.3% alone, to a cigarette smoke-induced injury alone (CSC 5%), or pre-incubated with TSP 0.3% for 1 hr before exposure to CSC 5% for 24h.
At the end of treatments, cell viability was determined by the Trypan Blue dye exclusion test, according to standard technique.
As reported in Fig. 1 , the percentage of cell survival was significantly lower in cultures exposed to CSC 5% as compared to control cultures grown in medium alone (59.95% and 83.08%, respectively; p<0.05), whereas, surprisingly, the toxic effect of CSC was significantly prevented by pre-incubation of cells with 0.3% TSP (p<0.05) since the percentage of cell survival on Calu-3 cultured with TSP alone or in association with CSC was similar to that reported for cell control (81.96% and 76.19%, respectively).
Fig. 1 shows Calu-3 survival cells after 24h of treatment with CSC 5% and/or TSP 0.3% by the Trypan Blue exclusion test. The data, representing the results of five experiments in triplicate, are expressed as the means + SEM. * = p<0.05 vs control cultures and § = p<0.05 vs CSC-treated samples.
The above-results demonstrate that TSP may contribute to the protection of the airway epithelium barrier against cigarette smoke-induced injury, by preserving epithelial barrier integrity.
Example 2
The necessary amount of tamarind seed polysaccharide (TSP) was weighted into a suitable vessel, water for injection was added up to the final volume (100 ml) until complete dissolution of the TSP. The isotonicity of the preparation was adjusted by
NaCl and pH adjusting agents were then added to maintain the pH within physiological pH (between 6.8 and 7.5). The so obtained preparation had the following composition:
TSP 0.3%
NaCl 0.9%,
Na2HP04 0.9%,
NaH2P04 0.09%
Water for injection to 100 ml
Following analogous procedure, the below preparation was obtained:
TSP 0.3%
NaCl 0.9%,
Citric acid 0.03%,
Sodium citrate 0.5%
Water for injection to 100 ml

Claims

1. Use of a polysaccharide polymer obtained from the seeds of the tamarind tree (tamarind seed polysaccharide), in protecting airway epithelial cells against tobacco smoke-induced damages.
2. Use according to claim 1 wherein tobacco smoke is cigarette smoke.
3. Use according to claim 2, wherein protection of airway epithelial cells against cigarette smoke-induced damages contributes to prevention of pathogenesis of the cigarette smoke-induced variety of acute and chronic respiratory disorders in cigarette smokers.
4. Use according to claim 2, wherein protection of airway epithelial cells against cigarette smoke-induced damages contributes to alleviation of the harm of the second-hand smoke to passive-smokers.
5. Use according to claim 1, wherein the polymer is locally administered to a subject in need thereof as a topical preparation.
6. Use according to claim 5, wherein the topical preparation is a preparation in the form of a liquid dosage form for topical application.
7. Use according to claim 6, wherein the liquid dosage form for topical application is an aerosolized liquid dosage form for topical application.
8. Use according to claim 5, wherein the preparation contains from 0.25 to 0.5% of the polysaccharide polymer obtained from the seeds of the tamarind tree.
9. Use according to claim 8 wherein the preparation contains 0.3% of the polysaccharide polymer obtained from the seeds of the tamarind tree.
10. Use according to claim 9, wherein the preparation further comprises a pH adjusting agent.
11. Use according to claim 10, wherein the pH adjusting agent is a buffering agent selected from monosodium phosphate (NaH2PC>4), disodium phosphate (Na2HP04), sodium citrate-citric acid system or mixture thereof.
12. A preparation in the form of a liquid dosage for topical application, which comprises a polysaccharide polymer obtained from the seeds of the tamarind tree, said preparation being useful in protecting airway epithelial cells against tobacco smoke-induced damages.
EP12735548.5A 2011-08-12 2012-07-17 Use of a polysaccharide polymer from the seeds of the tamarind tree in protecting against tobacco-associated damages Active EP2741754B1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
SI201230267T SI2741754T1 (en) 2011-08-12 2012-07-17 Use of a polysaccharide polymer from the seeds of the tamarind tree in protecting against tobacco-associated damages
PL12735548T PL2741754T3 (en) 2011-08-12 2012-07-17 Use of a polysaccharide polymer from the seeds of the tamarind tree in protecting against tobacco-associated damages
EP12735548.5A EP2741754B1 (en) 2011-08-12 2012-07-17 Use of a polysaccharide polymer from the seeds of the tamarind tree in protecting against tobacco-associated damages

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11006634 2011-08-12
PCT/EP2012/063975 WO2013023856A1 (en) 2011-08-12 2012-07-17 Use of a polysaccharide polymer from the seeds of the tamarind seed in protecting against tobacco-associated damages
EP12735548.5A EP2741754B1 (en) 2011-08-12 2012-07-17 Use of a polysaccharide polymer from the seeds of the tamarind tree in protecting against tobacco-associated damages

Publications (2)

Publication Number Publication Date
EP2741754A1 true EP2741754A1 (en) 2014-06-18
EP2741754B1 EP2741754B1 (en) 2015-05-27

Family

ID=46514378

Family Applications (1)

Application Number Title Priority Date Filing Date
EP12735548.5A Active EP2741754B1 (en) 2011-08-12 2012-07-17 Use of a polysaccharide polymer from the seeds of the tamarind tree in protecting against tobacco-associated damages

Country Status (14)

Country Link
EP (1) EP2741754B1 (en)
CN (1) CN103813798B (en)
BR (1) BR112014002934A2 (en)
CO (1) CO7061085A2 (en)
EA (1) EA024938B1 (en)
ES (1) ES2541761T3 (en)
HU (1) HUE025677T2 (en)
MX (1) MX357592B (en)
MY (1) MY170178A (en)
PL (1) PL2741754T3 (en)
PT (1) PT2741754E (en)
RS (1) RS54138B1 (en)
SI (1) SI2741754T1 (en)
WO (1) WO2013023856A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107892722A (en) * 2017-12-08 2018-04-10 云南猫哆哩集团食品有限责任公司 A kind of preparation method of water-soluble tamarind seed polysaccharide

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1283911B1 (en) * 1996-02-05 1998-05-07 Farmigea Spa VISCOSIZED OPHTHALMIC SOLUTIONS WITH TAMARIND GUM POLYSACCHARIDES
MX2012005818A (en) * 2010-07-12 2012-09-07 Zambon Spa Polysaccharide polymer from the seeds of the tamarind tree for use in treating dry cough.

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2013023856A1 *

Also Published As

Publication number Publication date
SI2741754T1 (en) 2015-09-30
CN103813798A (en) 2014-05-21
PT2741754E (en) 2015-09-11
WO2013023856A1 (en) 2013-02-21
EA024938B1 (en) 2016-11-30
EP2741754B1 (en) 2015-05-27
RS54138B1 (en) 2015-12-31
HUE025677T2 (en) 2016-04-28
MX2014001519A (en) 2014-05-27
CO7061085A2 (en) 2014-09-19
WO2013023856A8 (en) 2013-05-30
MY170178A (en) 2019-07-09
PL2741754T3 (en) 2015-10-30
ES2541761T3 (en) 2015-07-24
MX357592B (en) 2018-07-16
EA201490400A1 (en) 2014-05-30
CN103813798B (en) 2017-03-29
BR112014002934A2 (en) 2017-04-04

Similar Documents

Publication Publication Date Title
ES2332405T3 (en) A COMPOSITION OF LIQUID STAMPED NICOTINE FOR LUNG ADMINISTRATION.
US20230372262A1 (en) Composition for treating vascular disease, composition for reventing vascular disease, composition for treating hypertension, and composition for preventing hypertension
CA2388322C (en) Ciclesonide contained pharmaceutical composition for application to mucosa
EP2741754B1 (en) Use of a polysaccharide polymer from the seeds of the tamarind tree in protecting against tobacco-associated damages
TWI488656B (en) Tobramycin formulation
US9539248B2 (en) Agent for ameliorating chronic obstructive pulmonary disease
WO2019091082A1 (en) Solution preparation for aerosol inhalation of carbocisteine, and preparation method therefor
CN105456234A (en) Novel propellant asarone inhalation aerosol and preparation method thereof
CN109998151B (en) Use of medium chain triglycerides for improving and/or reducing respiratory tract irritation
EP2593119B1 (en) Polysaccharide polymer from the seeds of the tamarind tree for use in treating dry cough
WO2015135372A1 (en) Application of isoforskolin in preventing and treating chronic obstructive pulmonary disease
US20220022521A1 (en) New tobacco substitutes
MX2010009165A (en) Low-dose, non-irritating nicotine nasal composition to reduce the desire to smoke.
WO2015091288A1 (en) Aclidinium for use in the treatment of cough
NO120469B (en)

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20140130

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 36/48 20060101ALI20141127BHEP

Ipc: A61K 31/715 20060101AFI20141127BHEP

Ipc: A61K 9/00 20060101ALI20141127BHEP

Ipc: A61K 9/08 20060101ALI20141127BHEP

Ipc: A61P 11/00 20060101ALI20141127BHEP

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20150212

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 728464

Country of ref document: AT

Kind code of ref document: T

Effective date: 20150615

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602012007615

Country of ref document: DE

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2541761

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20150724

REG Reference to a national code

Ref country code: RO

Ref legal event code: EPE

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: KEMIA SA, CH

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20150728

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150827

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150527

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150527

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150527

REG Reference to a national code

Ref country code: PL

Ref legal event code: T3

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150927

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150527

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150828

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150527

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150527

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150527

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150527

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602012007615

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150717

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

REG Reference to a national code

Ref country code: HU

Ref legal event code: AG4A

Ref document number: E025677

Country of ref document: HU

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150731

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150731

26N No opposition filed

Effective date: 20160301

REG Reference to a national code

Ref country code: CH

Ref legal event code: AECN

Free format text: DAS PATENT IST AUFGRUND DES WEITERBEHANDLUNGSANTRAGS VOM 02.03.2016 REAKTIVIERT WORDEN.

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 5

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150717

PGRI Patent reinstated in contracting state [announced from national office to epo]

Ref country code: CH

Effective date: 20160526

Ref country code: LI

Effective date: 20160526

REG Reference to a national code

Ref country code: AT

Ref legal event code: UEP

Ref document number: 728464

Country of ref document: AT

Kind code of ref document: T

Effective date: 20150527

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150527

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150527

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150527

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150527

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 6

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150527

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 7

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150527

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230524

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: TR

Payment date: 20230707

Year of fee payment: 12

Ref country code: RO

Payment date: 20230707

Year of fee payment: 12

Ref country code: IT

Payment date: 20230720

Year of fee payment: 12

Ref country code: ES

Payment date: 20230804

Year of fee payment: 12

Ref country code: CZ

Payment date: 20230711

Year of fee payment: 12

Ref country code: CH

Payment date: 20230802

Year of fee payment: 12

Ref country code: AT

Payment date: 20230705

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SI

Payment date: 20230705

Year of fee payment: 12

Ref country code: RS

Payment date: 20230706

Year of fee payment: 12

Ref country code: PL

Payment date: 20230705

Year of fee payment: 12

Ref country code: HU

Payment date: 20230713

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20240726

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BG

Payment date: 20240709

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20240729

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20240729

Year of fee payment: 13

Ref country code: PT

Payment date: 20240708

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20240729

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20240725

Year of fee payment: 13